Cibc World Market Inc. Takes Position in Insulet Corporation $PODD

Cibc World Market Inc. bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) in the fourth quarter, Holdings Channel.com reports. The fund bought 5,286 shares of the medical instruments supplier’s stock, valued at approximately $1,502,000.

Other large investors have also recently made changes to their positions in the company. Nordea Investment Management AB raised its holdings in shares of Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares in the last quarter. ING Groep NV boosted its stake in shares of Insulet by 88.5% during the third quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after purchasing an additional 8,123 shares in the last quarter. Jain Global LLC boosted its stake in shares of Insulet by 148.2% during the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after purchasing an additional 63,719 shares in the last quarter. Fisher Asset Management LLC boosted its stake in shares of Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock valued at $14,286,000 after purchasing an additional 12,754 shares in the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock valued at $12,484,000 after purchasing an additional 9,206 shares in the last quarter.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.36% of the company’s stock.

Insulet Stock Performance

PODD stock opened at $159.61 on Wednesday. The firm has a market cap of $11.05 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 1.19 and a beta of 1.13. The firm has a 50-day simple moving average of $173.43 and a two-hundred day simple moving average of $235.68. Insulet Corporation has a one year low of $140.63 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities analysts forecast that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Raymond James Financial set a $216.00 price objective on shares of Insulet in a research note on Monday. Robert W. Baird dropped their price objective on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Leerink Partners dropped their price objective on shares of Insulet from $360.00 to $247.00 in a research note on Thursday, May 7th. The Goldman Sachs Group reiterated a “buy” rating and set a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Finally, Wall Street Zen upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Twenty-one analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $250.00.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.